89 related articles for article (PubMed ID: 11272198)
1. Expression of dominant-negative STAT5 inhibits growth hormone- and prolactin-induced proliferation of insulin-producing cells.
Galsgaard ED; Friedrichsen BN; Nielsen JH; Møldrup A
Diabetes; 2001 Feb; 50 Suppl 1():S40-1. PubMed ID: 11272198
[No Abstract] [Full Text] [Related]
2. Growth hormone- and prolactin-induced proliferation of insulinoma cells, INS-1, depends on activation of STAT5 (signal transducer and activator of transcription 5).
Friedrichsen BN; Galsgaard ED; Nielsen JH; Møldrup A
Mol Endocrinol; 2001 Jan; 15(1):136-48. PubMed ID: 11145745
[TBL] [Abstract][Full Text] [Related]
3. Signal transducer and activator of transcription 5 activation is sufficient to drive transcriptional induction of cyclin D2 gene and proliferation of rat pancreatic beta-cells.
Friedrichsen BN; Richter HE; Hansen JA; Rhodes CJ; Nielsen JH; Billestrup N; Møldrup A
Mol Endocrinol; 2003 May; 17(5):945-58. PubMed ID: 12586844
[TBL] [Abstract][Full Text] [Related]
4. Regulation of prolactin receptor (PRLR) gene expression in insulin-producing cells. Prolactin and growth hormone activate one of the rat prlr gene promoters via STAT5a and STAT5b.
Galsgaard ED; Nielsen JH; Møldrup A
J Biol Chem; 1999 Jun; 274(26):18686-92. PubMed ID: 10373481
[TBL] [Abstract][Full Text] [Related]
5. Prolactin regulation of islet-derived INS-1 cells: characteristics and immunocytochemical analysis of STAT5 translocation.
Stout LE; Svensson AM; Sorenson RL
Endocrinology; 1997 Apr; 138(4):1592-603. PubMed ID: 9075720
[TBL] [Abstract][Full Text] [Related]
6. An immunohistochemical approach to monitor the prolactin-induced activation of the JAK2/STAT5 pathway in pancreatic islets of Langerhans.
Brelje TC; Svensson AM; Stout LE; Bhagroo NV; Sorenson RL
J Histochem Cytochem; 2002 Mar; 50(3):365-83. PubMed ID: 11850439
[TBL] [Abstract][Full Text] [Related]
7. Distinctive roles for prolactin and growth hormone in the activation of signal transducer and activator of transcription 5 in pancreatic islets of langerhans.
Brelje TC; Stout LE; Bhagroo NV; Sorenson RL
Endocrinology; 2004 Sep; 145(9):4162-75. PubMed ID: 15142985
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of oncogene STAT3 phosphorylation by a prolactin antagonist, hPRL-G129R, in T-47D human breast cancer cells.
Cataldo L; Chen NY; Yuan Q; Li W; Ramamoorthy P; Wagner TE; Sticca RP; Chen WY
Int J Oncol; 2000 Dec; 17(6):1179-85. PubMed ID: 11078803
[TBL] [Abstract][Full Text] [Related]
9. Human prolactin (hPRL) antagonists inhibit hPRL-activated signaling pathways involved in breast cancer cell proliferation.
Llovera M; Pichard C; Bernichtein S; Jeay S; Touraine P; Kelly PA; Goffin V
Oncogene; 2000 Sep; 19(41):4695-705. PubMed ID: 11032019
[TBL] [Abstract][Full Text] [Related]
10. Expression of functional prolactin receptors in nonpregnant human endometrium: janus kinase-2, signal transducer and activator of transcription-1 (STAT1), and STAT5 proteins are phosphorylated after stimulation with prolactin.
Jabbour HN; Critchley HO; Boddy SC
J Clin Endocrinol Metab; 1998 Jul; 83(7):2545-53. PubMed ID: 9661641
[TBL] [Abstract][Full Text] [Related]
11. The activity of transcription factor Stat5 responds to prolactin, growth hormone, and IGF-I in rat and bovine mammary explant culture.
Yang J; Kennelly JJ; Baracos VE
J Anim Sci; 2000 Dec; 78(12):3114-25. PubMed ID: 11132826
[TBL] [Abstract][Full Text] [Related]
12. The effect of suppressor of cytokine signaling 3 on GH signaling in beta-cells.
Rønn SG; Hansen JA; Lindberg K; Karlsen AE; Billestrup N
Mol Endocrinol; 2002 Sep; 16(9):2124-34. PubMed ID: 12198248
[TBL] [Abstract][Full Text] [Related]
13. STAT5 activation is required for interleukin-9-dependent growth and transformation of lymphoid cells.
Demoulin JB; Uyttenhove C; Lejeune D; Mui A; Groner B; Renauld JC
Cancer Res; 2000 Jul; 60(14):3971-7. PubMed ID: 10919676
[TBL] [Abstract][Full Text] [Related]
14. Stimulation of pancreatic beta-cell proliferation by growth hormone is glucose-dependent: signal transduction via janus kinase 2 (JAK2)/signal transducer and activator of transcription 5 (STAT5) with no crosstalk to insulin receptor substrate-mediated mitogenic signalling.
Cousin SP; Hügl SR; Myers MG; White MF; Reifel-Miller A; Rhodes CJ
Biochem J; 1999 Dec; 344 Pt 3(Pt 3):649-58. PubMed ID: 10585851
[TBL] [Abstract][Full Text] [Related]
15. Regulation of the rat liver sodium-dependent bile acid cotransporter gene by prolactin. Mediation of transcriptional activation by Stat5.
Ganguly TC; O'Brien ML; Karpen SJ; Hyde JF; Suchy FJ; Vore M
J Clin Invest; 1997 Jun; 99(12):2906-14. PubMed ID: 9185514
[TBL] [Abstract][Full Text] [Related]
16. Disruption of steroid and prolactin receptor patterning in the mammary gland correlates with a block in lobuloalveolar development.
Grimm SL; Seagroves TN; Kabotyanski EB; Hovey RC; Vonderhaar BK; Lydon JP; Miyoshi K; Hennighausen L; Ormandy CJ; Lee AV; Stull MA; Wood TL; Rosen JM
Mol Endocrinol; 2002 Dec; 16(12):2675-91. PubMed ID: 12456789
[TBL] [Abstract][Full Text] [Related]
17. The 20-kilodalton (kDa) human growth hormone (hGH) differs from the 22-kDa hGH in the effect on the human prolactin receptor.
Tsunekawa B; Wada M; Ikeda M; Uchida H; Naito N; Honjo M
Endocrinology; 1999 Sep; 140(9):3909-18. PubMed ID: 10465259
[TBL] [Abstract][Full Text] [Related]
18. Growth hormone, but not prolactin, maintains, low-level activation of STAT5a and STAT5b in female rat liver.
Choi HK; Waxman DJ
Endocrinology; 1999 Nov; 140(11):5126-35. PubMed ID: 10537141
[TBL] [Abstract][Full Text] [Related]
19. Synergistic action of prolactin (PRL) and androgen on PRL-inducible protein gene expression in human breast cancer cells: a unique model for functional cooperation between signal transducer and activator of transcription-5 and androgen receptor.
Carsol JL; Gingras S; Simard J
Mol Endocrinol; 2002 Jul; 16(7):1696-710. PubMed ID: 12089361
[TBL] [Abstract][Full Text] [Related]
20. Suppression of Pdx-1 perturbs proinsulin processing, insulin secretion and GLP-1 signalling in INS-1 cells.
Wang H; Iezzi M; Theander S; Antinozzi PA; Gauthier BR; Halban PA; Wollheim CB
Diabetologia; 2005 Apr; 48(4):720-31. PubMed ID: 15756539
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
